Ling Wang

Geron Shares Seen Range-Bound On Lack Of Major Data Until Late 2017

BTIG Sets $12 Price Target On Rockwell Medical, Sees 63% Upside

Why This Analyst Is Awaiting More Efficacy Signals For Agios Pharma Candidates

BTIG Sets $12 Price Target On Rockwell Medical, Sees 63% Upside

Why This Analyst Is Awaiting More Efficacy Signals For Agios Pharma Candidates

Tracon's Promising Tumor Treatments Make The Stock A Buy

Ophthotech's Fovista Has Potential To Break Through The 'Therapeutic Ceiling' Of Anti-VEGF Therapies

Tracon's Promising Tumor Treatments Make The Stock A Buy

Ophthotech's Fovista Has Potential To Break Through The 'Therapeutic Ceiling' Of Anti-VEGF Therapies

Expect Merrimack Pharma Shares To Be Range-Bound For The Near Term

Acceleron Has 2 Phase III Trials With Good Chance Of Success; BTIG Initiates Stock At Buy

Ling Wang Recent News

Why Oppenheimer Still Thinks Rockwell Medical Could Double

35 Stock Ideas Oppenheimer Analysts Love Right Now

8 Oppenheimer Analysts Choose Their Favorite Healthcare Stocks

UPDATE: Oppenheimer Initiates Coverage On Rockwell Medical On Significant Expected Upside

Brean Murray Carret & Co. Maintains Buy Rating On ImmunoGen, Inc. (IMGN)

Brean Murray Carret Reiterates Buy On Immunogen (IMGN)